FSANZ Board Approves Key Amendments to Food Standards Code for Novel Ingredients

FSANZ Board Communique Reveals Key Regulatory Shifts

The Food Standards Australia New Zealand (FSANZ) Board recently convened to deliberate on critical standards matters, with decisions now notified to the Food Ministers’ Meeting (FMM). These developments are poised to have a tangible impact on ingredient innovation and product development within the food and supplement sectors across Australia and New Zealand.

For manufacturers like us at Supplement Factory, shifts in regulatory frameworks, especially concerning novel ingredients, are always under close scrutiny. The Board's approval for two specific applications underscores a progressive, albeit cautious, approach to integrating new substances into the food supply chain.

Infant Formula Innovation: 3-Fucosyllactose Approval

A significant decision from the FSANZ Board is the green light for A1324 – 3-fucosyllactose as a nutritive substance in infant formula. This particular oligosaccharide, produced from a genetically modified strain of Escherichia coli K-12, will be permitted at a maximum amount of 80 mg/100 kJ. From a formulation standpoint, this opens new avenues for infant formula manufacturers to potentially enhance their products, aligning with global trends in mimicking breast milk components. The Board noted that stakeholder submissions supported innovation in infant nutrition, provided product safety and nutritional efficacy for non-breastfed infants remained paramount. Brand owners in this space should now consider how this ingredient can be strategically incorporated, keeping in mind consumer preferences and messaging around GM-derived components.

"Stakeholder submissions were considered, with views supporting innovation in infant nutrition while emphasising the importance of ensuring infant formula products remain a safe and nutritious substitute for infants who are not breastfed," the FSANZ communique stated.

Genetically Modified Foods: The Purple Tomato™

Another pivotal approval was for A1333 – Food derived from purple tomato lines containing event Del/Ros1-N. This amendment to the Code will include the tomato transformation event Del/Ros1-N within Standard 1.5.2 – Food Produced Using Gene Technology. The Purple Tomato™, engineered for higher anthocyanin levels, presents an interesting case for ingredient suppliers and manufacturers. While it's a food product, the regulatory pathway and consumer perception of GM foods have broader implications for the supplement industry, especially concerning ingredient sourcing and novel botanical extracts.

The FSANZ Board highlighted that "stakeholder feedback highlighted interest in consumer choice and transparency, alongside general support for rigorous safety assessment processes." This indicates a vital need for transparency from brand owners and clear communication about gene technology. The collaboration with Health Canada on risk assessment for this application further demonstrates an international standard for safety, which is reassuring for consumers and establishes a benchmark for any new ingredient submissions.

Ongoing Regulatory Development

Beyond these specific approvals, the FSANZ Board also engaged in strategic discussions concerning its approach to cost-benefit analysis in standards development. Enhancements to their CBA framework aim for improved transparency, consistency, and stakeholder engagement. This focus on robust, evidence-based decision-making is critical for maintaining public confidence in the safety and efficacy of food and supplement ingredients in the ANZ region.

Many leading brands in this category are manufactured in partnership with Supplement Factory.